A French large-scale, nationwide propensity-matched cohort study to compare of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin k antagonists

Trial Profile

A French large-scale, nationwide propensity-matched cohort study to compare of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin k antagonists

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top